Literature DB >> 27622162

Rotavirus gastroenteritis in children less than five years of age in primary care settings in Bulgaria: an observational study.

Mayda Tiholova1, Kusuma Gopala2, Magda Berberova3, Margarita Strokova-Stoilova3, Monica Tafalla4.   

Abstract

BACKGROUND: Rotavirus (RV) causes a high proportion of acute gastroenteritis (AGE) cases, especially among children under the age of five years old. This surveillance study was undertaken to study the incidence and severity of rotavirus gastroenteritis (RVGE) in primary care settings in Bulgaria over a one-year period.
METHODS: In this prospective, observational study of AGE cases in children under five years of age presenting in the primary care setting over a one year period, stool samples were collected and tested for RV using a rapid visual immunochromatographic test kit. After the first visit, parents monitored their child for about two weeks and reported the symptoms experienced by the child during the follow-up period to the physician in a follow-up phone call. The percentage of RVGE cases among AGE was calculated and the severity of AGE (according to the 20-point Vesikari scale) was assessed by the physician based on the symptoms reported by the parents. The seasonality of RVGE was also studied.
RESULTS: The proportion of RVGE among the 624 AGE cases examined was 25.5%. Severe AGE was experienced by 81.8% RV-positive and 54.6% RV-negative children (p-value <0.001) and a third of all severe AGE cases occurred in RV-positive patients. A multivariate logistic regression analysis of the determinants of hospitalization indicated that severity of disease and RV-positivity were the statistically significant variables explaining hospitalization of AGE cases; even controlling for severity, RV-positive patients were more often hospitalized than RV-negative ones. RVGE cases occurred throughout the year, with peaks during August and September.
CONCLUSION: Our study emphasizes that RV is an important cause of AGE in children under five presenting in primary care settings in Bulgaria and a disproportionately high proportion of severe AGE cases may be attributed to RV infections. TRIAL REGISTRATION NUMBER: NCT01733849.

Entities:  

Keywords:  RV disease burden; Rotavirus; acute gastroenteritis; primary care settings

Year:  2016        PMID: 27622162      PMCID: PMC5018391          DOI: 10.11599/germs.2016.1095

Source DB:  PubMed          Journal:  Germs        ISSN: 2248-2997


  21 in total

1.  Genetic characterization of Bulgarian rotavirus isolates and detection of rotavirus variants: challenges for the rotavirus vaccine program?

Authors:  Zornitsa Mladenova; Miren Iturriza-Gomara; Mathew D Esona; James Gray; Neli Korsun
Journal:  J Med Virol       Date:  2011-02       Impact factor: 2.327

2.  Burden of rotavirus-associated and non-rotavirus-associated diarrhea among nonhospitalized individuals in central Italy: a 1-year sentinel-based epidemiological and virological surveillance.

Authors:  Filippo Ansaldi; Piero Lai; Laura Valle; Rosamaria Riente; Paolo Durando; Laura Sticchi; Pierluigi Tucci; Paolo Biasci; Pietro Crovari; Roberto Gasparini; Giancarlo Icardi
Journal:  Clin Infect Dis       Date:  2008-03-15       Impact factor: 9.079

Review 3.  Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries.

Authors:  Carlo Giaquinto; Geraldine Dominiak-Felden; Pierre Van Damme; Tin Tin Htar Myint; Yvonne A Maldonado; Vana Spoulou; T Christopher Mast; Mary Allen Staat
Journal:  Hum Vaccin       Date:  2011-07-01

4.  Rotavirus vaccine and intussusception:report from an expert consultation.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2011-07-22

Review 5.  2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Jacqueline E Tate; Anthony H Burton; Cynthia Boschi-Pinto; A Duncan Steele; Jazmin Duque; Umesh D Parashar
Journal:  Lancet Infect Dis       Date:  2011-10-24       Impact factor: 25.071

Review 6.  Impact of rotavirus vaccines on rotavirus disease.

Authors:  Philippe Lepage; Anne Vergison
Journal:  Expert Rev Anti Infect Ther       Date:  2012-05       Impact factor: 5.091

7.  International variation in disease burden of rotavirus gastroenteritis in children with community- and nosocomially acquired infection.

Authors:  M Frühwirth; U Heininger; B Ehlken; G Petersen; B Laubereau; I Moll-Schüler; I Mutz; J Forster
Journal:  Pediatr Infect Dis J       Date:  2001-08       Impact factor: 2.129

8.  Rotavirus vaccines: considerations for successful implementation in Europe.

Authors:  Pierre Van Damme; Marie Van der Wielen; Filippo Ansaldi; Daniel Desgrandchamps; Javier Diez Domingo; Francisco Gimenez Sanchez; Jim Gray; Martin Haditsch; Kari Johansen; Paula Lorgelly; Mathie Lorrot; Nathalie Parez; Volkmar Reschke; Markus Rose
Journal:  Lancet Infect Dis       Date:  2006-12       Impact factor: 25.071

9.  Rotavirus vaccination in central Europe.

Authors:  Zsófia Mészner; Ioana Anca; Francis André; Roman Chlibek; Milan Čižman; Paweł Grzesiowski; Atanas Mangarov; Marko Pokorn; Roman Prymula; Darko Richter; Nuran Salman; Pavol Šimurka; Eda Tamm; Goran Tešović; Ingrid Urbancikova; Vytautas Usonis; Dace Zavadska
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-06       Impact factor: 2.839

Review 10.  A critical literature review of health economic evaluations of rotavirus vaccination.

Authors:  Samuel Aballéa; Aurélie Millier; Sibilia Quilici; Stuart Caroll; Stavros Petrou; Mondher Toumi
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 3.452

View more
  1 in total

1.  Primary care-based surveillance to estimate the proportion of rotavirus gastroenteritis among Latvian children below 5 years of age with acute gastroenteritis.

Authors:  Monica Tafalla; Dace Gardovska; Kusuma Gopala; Liga Kozlovska
Journal:  Hum Vaccin Immunother       Date:  2018-10-31       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.